Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR)
Noni Novisari Soeroso
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Health Professions Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Deciphering the Coagulation Factors in Pulmonary Embolism Incident-Based Thorax Enhanced Chest CT in COVID-19 Patient Wan Betty Pratiwi; Noni Novisari Soeroso; Setia Putra Tarigan; Muntasir Abdullah; Rosita Juwita Sembiring; Azizah Ghanie Icksan; Netty Delvrita Lubis; Putri Chairani Eyanoer
Jurnal Respirasi Vol. 9 No. 2 (2023): May 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.2.2023.93-100

Abstract

Introduction: Pulmonary embolism is associated with coagulopathy in COVID-19. It is one of the causes of death in COVID-19 cases and is often underdiagnosed in Indonesia because computed tomography-pulmonary angiography (CTPA) is not used as the gold standard. T Methods: This study used a prospective analytical design with a cross-sectional approach. The study participants were 45 COVID-19 patients admitted to Santa Elisabeth Hospital, Medan, from January to March 2021.  Patients were identified with moderate to severe degrees of COVID-19 and elevated D-dimer and subsequently instructed to undergo a thorax CT scan with IV contrast. The data was analyzed using dependent t-test statistical analysis. The p-value < 0.05 was noted as significant. Results: Moderate to severe coagulation factor values in COVID-19 patients with mean + SD PT, APTT, D-dimer, fibrinogen, and platelets were 14.11; 30.65; 1172.14; 423.56 and 215.822, respectively. In this study, 22 (48.9%) patients experienced a pulmonary embolism, while the other 23 (51.1%) did not. No significant correlation was found between all coagulation factors and embolism (p > 0.05). The mean + SD well score for pulmonary embolism was 0.23 + 0.57. Conclusion: Pulmonary embolism was detected in 22 patients (48.49%) with moderate to severe COVID-19 who developed hypercoagulation as indicated by the thorax CT scan with IV contrast. This case was quite common. In resource-constrained situations, a thorax CT scan with IV contrast may replace CTPA in diagnosing/detecting the presence of pulmonary embolism.
Double-Lumen vs Small-Bore Pigtail Catheter for Pleural Effusion: Which is Superior? Novi Andriani Siagian; Noni Novisari Soeroso; Syamsul Bihar; Taufik Ashar
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.39-46

Abstract

Introduction: Pleural effusion is associated with a high mortality rate. Tube thoracostomy remains the standard treatment. Despite this, double-lumen catheters, typically used for central venous access, are infrequently employed for pleural drainage. This study compared the characteristics of patients undergoing double-lumen catheter versus pigtail catheter placements for pleural effusion. Methods: A retrospective cross-sectional study was conducted on adult patients at Prof. Dr. Chairuddin Panusunan Lubis Universitas Sumatera Utara Hospital, Haji Adam Malik General Hospital, and St. Elisabeth Hospital, Medan, from September 2022 to April 2024. This study analyzed patient demographics and clinical presentations for those receiving either catheter type. Results: The mean age of patients with double-lumen catheters was 58.21 years old, while those with pigtail catheters averaged 54.9 years old. Patients with double-lumen catheters frequently presented with a combination of shortness of breath, cough, and chest pain, while those with pigtail catheters primarily reported shortness of breath. Both groups predominantly exhibited exudative pleural effusions. Radiological evaluations indicated moderate pleural effusion was most common in both groups, with thoracic ultrasound revealing fluid volumes between 500 and 2,000 cc. Conclusion: Double-lumen catheters are more frequently utilized for moderate to massive pleural effusion, whereas pigtail catheters are typically reserved for moderate cases. The choice of catheter depends on the patient's condition, the underlying cause of the effusion, and radiological findings.
The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia Elisna Syahruddin; Noni Novisari Soeroso; Fannie Rizki Ananda; Laksmi Wulandari; Ana Rima Setijadi; Sabrina Ermayanti; Suryanti Dwi Pratiwi; Andreas Infianto; Novita Andayani; Sri Melati Munir; Avissena Dutha Pratama; Ida Ayu Jasminarti Dwi Kusumawardani; Haryati Haryati; Natalie Duyen; Muhammad Alfin Hanif; Darren Wan-Teck Lim
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.22-30

Abstract

Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer patients treated with first- and second-generation EGFR-TKI. Methods: Based on cytology and histological results, this cross-sectional study included 1,008 participants diagnosed with lung adenocarcinoma (LUAD) from 11 Indonesian Respiratory Centers. Every three months, the response to treatment was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria in 1.1. Significant differences in the clinical features of the three TKI treatment groups were identified using logistic regression analysis, the median time to disease progression was estimated using the Kaplan-Meier technique, and independent prognostic factors related to the time to progression (TTP) were assessed using Cox proportional hazards regression. Results: This study examined 505 patients, the majority of whom were females (50.9%), never smoked (59.8%), diagnosed at an advanced stage (99.2%), and had an Eastern Cooperative Oncology Group (ECOG) scale of 0-1 (83.2%). Approximately 98.1% of patients were treated with afatinib (14.8%), erlotinib (18.6%), and gefitinib (66.1%) due to common mutations. The groups did not differ significantly (p>0.05). The median overall survival (OS) rate was 9 months. The time to LUAD progression in lung cancer was significantly impacted by poor performance (p=0.001). Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitor treatment can only prolong the TTP of LUAD by up to 9 months, and the performance scale when receiving the EGFR-TKI significantly affects the prognosis.
Anaplastic Lymphoma Kinase (ALK) Rearrangement of Lung Adenocarcinoma among North Sumatera Population Muhammad Yusuf Adira Putra; Noni Novisari Soeroso; Elisna Syahruddin; Evlina Suzanna; Dina Afiani; Taufik Ashar; Darren Wan-Teck Lim
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.47-53

Abstract

Introduction: Lung cancer is a malignancy of the lung parenchyma or bronchi. Molecular targeted therapy directed at oncogene driver mutations, such as anaplastic lymphoma kinase (ALK), improves the prognosis of patients with non-small cell lung carcinoma (NSCLC). This study aimed to determine the characteristics of lung adenocarcinoma patients and the prevalence of ALK rearrangement among the North Sumatra population. Methods: This descriptive study used data from patients' formalin-fixed paraffin-embedded (FFPE) ALK examination results and medical records. The laboratory analyzed the patient’s FFPE for ALK fusion protein expression using the VENTANA anti-ALK (D5F3) procedure to determine the prevalence of ALK rearrangement. Results: Of the 34 subjects, it was revealed that the characteristics of lung adenocarcinoma patients were 18 patients aged >60 years old (52.9%), 26 male patients (76.4%), and 24 heavy smoker patients (70.6%). Based on the pathological tumor-node-metastasis (pTNM) stage, most samples were classified as stage IVA, with 24 cases (70.6%) showing the highest metastases to the pleura. There were 2 cases of ALK mutations obtained through immunohistochemical examination with a percentage of 5.8%. Conclusion: There are relatively few ALK rearrangement mutations in lung adenocarcinoma patients without screening. Additional research is needed to ascertain the distribution of lung adenocarcinoma patient characteristics associated with a higher prevalence of ALK rearrangement mutations.
Co-Authors Ana Rima Setijadi Andreas Infianto Avissena Dutha Pratama Azizah Ghanie Icksan Darren Wan-Teck Lim Dina Afiani Elisna Syahruddin Ermayanti, Sabrina Evlina Suzanna Fannie Rizki Ananda Haryati Haryati Ida Ayu Jasminarti Dwi Kusumawardani Laksmi Wulandari Muhammad Alfin Hanif Muhammad Yusuf Adira Putra Muntasir Abdullah Natalie Duyen Netty Delvrita Lubis Novi Andriani Siagian Novita Andayani Putri Chairani Eyanoer, Putri Chairani Rosita Juwita Sembiring Sri Melati Munir Suryanti Dwi Pratiwi Syamsul Bihar Tarigan, Setia Putra Taufik Ashar Wan Betty Pratiwi